Another phase I clinical trial using a peptide vaccine against VEGFR-1 was performed for advanced solid tumors, and activation of peptide-specific CTLs was also demonstrated [157]
Another phase I clinical trial using a peptide vaccine against VEGFR-1 was performed for advanced solid tumors, and activation of peptide-specific CTLs was also demonstrated [157]. Over UNC1215 80% of gliomas are astrocytic tumors, including glioblastoma (GBM), the most malignant…